On February 12, 2019, the FDA plans to convene an Advisory Committee Meeting to share the available evidence and seek expert opinion on the evaluation of the benefits and risks of trans-vaginal mesh devices for anterior pelvic organ prolapse. This will provide an opportunity for the FDA to hear directly from the public, including patients, about their experiences, and consider additional regulatory actions.
Read More